Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
1998
|
| gptkbp:ATCCode |
gptkb:J05AG03
|
| gptkbp:CASNumber |
gptkb:154598-52-4
|
| gptkbp:chemicalFormula |
C14H9ClF3NO2
|
| gptkbp:contraindication |
severe liver disease
|
| gptkbp:drugClass |
non-nucleoside reverse transcriptase inhibitor
|
| gptkbp:eliminationHalfLife |
40-55 hours
|
| gptkbp:genericName |
gptkb:efavirenz
|
| https://www.w3.org/2000/01/rdf-schema#label |
Sustiva
|
| gptkbp:indication |
antiretroviral therapy
|
| gptkbp:interactsWith |
gptkb:rifampin
gptkb:voriconazole gptkb:St._John's_Wort |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Bristol-Myers_Squibb
|
| gptkbp:metabolism |
liver
|
| gptkbp:pregnancyCategory |
D
|
| gptkbp:pregnancyWarning |
may cause birth defects
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
dizziness
rash insomnia impaired concentration |
| gptkbp:synonym |
gptkb:Stocrin
|
| gptkbp:usedFor |
HIV infection
|
| gptkbp:bfsParent |
gptkb:efavirenz
|
| gptkbp:bfsLayer |
6
|